ResearchMoz

Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth

GBI Research
Published Date » 2012-12-14
No. Of Pages » 120
     
  Rheumatology Therapeutics Market to 2018 Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth  
     
  Summary  
   
 GBI Research, the leading business intelligence provider, has released its latest research, Rheumatology Therapeutics Market to 2018 Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth. The report provides insights into the rheumatology therapeutics market forecasts until 2018 and examines global treatment usage patterns for various rheumatology disorders. It also looks at the geographical distribution of the rheumatology disorders therapeutics market across key geographies (the US, the top five countries of Europe, and Japan) and provides insights into the...
Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9

2 Rheumatology Therapeutics Market to 2018 - Introduction 11
2.1 Introduction 11

3 Rheumatology Therapeutics Market to 2018 - Market Overview 12
3.1 Introduction 12
3.1.1 Revenue 14
3.1.2 Annual Cost of Treatment 16
3.1.3 Treatment Usage Pattern 18

4 Rheumatology Therapeutics Market to 2018 - Geographical Landscape Revenue Analysis by Geography 20
4.1 The US 20
4.1.1 Revenue 21
4.1.2 Annual Cost of Treatment 22
4.1.3 Treatment Usage Patterns 24
4.2 Top Five Countries of Europe 26
4.2.1 Introduction 26
4.2.2 Revenue 26
4.2.3 Annual Cost of Treatment 29
4.2.4 Treatment Usage Patterns 30
4.3 Japan 32
4.3.1 Revenue 32
4.3.2 Annual Cost of Treatment 34
4.3.3 Treatment Usage Patterns 36
4.4 Australia 38
4.4.1 Overview of Rheumatology Market 38
4.5 China 40
4.5.1 Revenue 40
4.6 India 42
4.6.1 Overview of Rheumatology Market 42

5 Rheumatology Therapeutics Market to 2018 - Therapeutic Landscape 44
5.1 Rheumatoid Arthritis Therapeutics Market 44
5.1.1 Introduction 44
5.1.2 Revenue 45
5.1.3 Revenue by Country 48
5.1.4 Annual Cost of Treatment 50
5.1.5 Treatment Usage Pattern 51
5.1.6 Treatment Flow Algorithm 53
5.1.7 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 53
5.2 Osteoarthritis Therapeutics Market 55
5.2.1 Introduction 55
5.2.2 Revenue 55
5.2.3 Revenue by Country 59
5.2.4 Annual Cost of Treatment 61
5.2.5 Treatment Flow Algorithm 62
5.2.6 Treatment Usage Pattern 63
5.2.7 Drivers and Barriers for the Osteoporosis Therapeutics Market 65
5.3 Gout Therapeutics Market 66
5.3.1 Introduction 66
5.3.2 Revenue 66
5.3.3 Revenue by Country 70
5.3.4 Annual Cost of Treatment 72
5.3.5 Treatment Usage Pattern 73
5.3.6 Treatment Flow Algorithm 75
5.3.7 Drivers and Barriers for the Gout Therapeutics Market 75
5.4 Systemic Lupus Erythematosus Therapeutics Market 77
5.4.1 Introduction 77
5.4.2 Revenue 78
5.4.3 Annual Cost of Treatment 83
5.4.4 Treatment Usage Pattern 85
5.4.5 Treatment Flow Algorithm 87
5.4.6 Drivers and Barriers for Systemic Lupus Erythematosus Therapeutics Market 87

6 Rheumatology Therapeutics Market to 2018 - Pipeline Analysis 89

6.1 Pipeline Assessment by Clinical Phase of Development 89
6.2 Key R&D Trends and Future Outlook 90
6.3 Profiles of Promising Molecules 91
6.3.1 Tofacitinib 91
6.3.2 Fostamatinib 91
6.3.3 LY2127399 (tabalumab) 92
6.3.4 Naproxcinod 92
6.3.5 RDEA594 (lesinurad) 92
6.3.6 BCX4208 93
6.3.7 Epratuzumab 94
6.3.8 Lupuzor 94
6.3.9 Atacicept 94

7 Rheumatology Therapeutics Market to 2018 - Competitive Landscape 95
7.1 Abbott 95
7.1.1 Overview 95
7.1.2 Major Marketed Products 95
7.1.3 SWOT Analysis 96
7.2 Amgen 97
7.2.1 Overview 97
7.2.2 Major Marketed Products 97
7.2.3 SWOT Analysis 98
7.3 Pfizer 99
7.3.1 Overview 99
7.3.2 Major Marketed Products 99
7.3.3 SWOT Analysis 100
7.4 Janssen Biotech 101
7.4.1 Overview 101
7.4.2 Major Marketed Products 101
7.4.3 SWOT Analysis 102
7.5 Merck 103
7.5.1 Overview 103
7.5.2 Major Marketed Products 103
7.5.3 SWOT Analysis 104

8 Rheumatology Therapeutics Market to 2018 - Strategic Consolidations 105
8.1 Overview 105
8.1.1 Deals by Type of Agreement 106
8.1.2 Deals by Year 107
8.1.3 Deals by Geography 108
8.1.4 Profiling of Major Deals 109

9 Rheumatology Therapeutics Market - Appendix 113
9.1 Market Definitions 113
9.2 Abbreviations 113
9.3 Bibliography 113
9.4 Research Methodology 116
9.4.1 Coverage 116
9.4.2 Secondary Research 116
9.4.3 Primary Research 117
9.5 Therapeutic Landscape 117
9.5.1 Epidemiology-based Forecasting 118
9.5.2 Market Size by Geography 119
9.6 Geographical Landscape 120
9.7 Pipeline Analysis 120
9.8 Competitive Landscape 120
9.8.1 Expert Panel Validation 120
9.9 Contact Us 120
9.10 Disclaimer 120

List of Tables


Table 1: Rheumatology Therapeutics Market, Global, Revenue ($bn), 2005-2011 14
Table 2: Rheumatology Therapeutics Market, Global, Revenue Forecasts ($bn),  2011-2018 14
Table 3: Rheumatology Therapeutics Market, Global, Annual Cost of Therapy ($),  2005-2011 16
Table 4: Rheumatology Therapeutics Market, Global, Annual Cost of Therapy ($),  2011-2018 16
Table 5: Rheumatology Therapeutics Market, Global, Treatment Usage Patterns (million), 2005-2011 18
Table 6: Rheumatology Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018 18
Table 7: Rheumatology Therapeutics Market, The US, Revenue ($bn), 2005-2011 21
Table 8: Rheumatology Therapeutics Market, The US, Revenue Forecasts ($bn),  2011-2018 21
Table 9: Rheumatology Therapeutics Market, The US, Annual Cost of Therapy ($),  2005-2011 22
Table 10: Rheumatology Therapeutics Market, The US, Annual Cost of Therapy ($),  2011-2018 22
Table 11: Rheumatology Therapeutics Market, The US, Treatment Usage Patterns (million), 2005-2011 24
Table 12: Rheumatology Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2018 24
Table 13: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2005-2011 26
Table 14: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018 26
Table 15: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2005-2011 27
Table 16: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2011-2018 28
Table 17: Rheumatology Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2005-2011 29
Table 18: Rheumatology Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2011-2018 29
Table 19: Rheumatology Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2005-2011 30
Table 20: Rheumatology Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2011-2018 30
Table 21: Rheumatology Therapeutics Market, Japan, Revenue ($bn), 2005-2011 32
Table 22: Rheumatology Therapeutics Market, Japan, Revenue Forecasts ($bn), 2011-2018 33
Table 23: Rheumatology Therapeutics Market, Japan, Annual Cost of Therapy ($),  2005-2011 35
Table 24: Rheumatology Therapeutics Market, Japan, Annual Cost of Therapy ($),  2011-2018 35
Table 25: Rheumatology Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2005-2011 36
Table 26: Rheumatology Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2011-2018 36
Table 27: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2005-2011 47
Table 28: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 47
Table 29: Rheumatoid Arthritis Therapeutics Market, Global, Revenue by Country ($m), 2005-2011 48
Table 30: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018 49
Table 31: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2011 50
Table 32: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 50
Table 33: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Pattern (million), 2005-2011 51
Table 34: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Pattern (million), 2011-2018 51
Table 35: Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2005-2011 57
Table 36: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn),  2011-2018 57
Table 37: Osteoarthritis Therapeutics Market, Global, Revenue ($m), 2005-2011 59
Table 38: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 60
Table 39: Osteoarthritis Therapeutics Market, Global, Annual Cost of Therapy ($),  2005-2011 61
Table 40: Osteoarthritis Therapeutics Market, Global, Annual Cost of Therapy ($),  2011-2018 61
Table 41: Osteoarthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2005-2011 63
Table 42: Osteoarthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2011-2018 63
Table 43: Gout Therapeutics Market, Global, Revenue ($m), 2005-2011 68
Table 44: Gout Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 68
Table 45: Gout Therapeutics Market, Global, Revenue by Country ($m), 2005-2011 70
Table 46: Gout Therapeutics Market, Global, Revenue Forecasts by Country ($m),  2011-2018 71
Table 47: Gout Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2011 72
Table 48: Gout Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 72
Table 49: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions),  2005-2011 73
Table 50: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions),  2011-2018 73
Table 51: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue ($m), 2005-2011 80
Table 52: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 80
Table 53: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue by Country ($m), 2005-2011 81
Table 54: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018 82
Table 55: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2011 83
Table 56: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 83
Table 57: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2005-2011 85
Table 58: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2011-2018 85
Table 59: Rheumatology Therapeutics Market, Global, Deals by Type of Agreement (%), 2007-2012 106
Table 60: Rheumatology Therapeutics Market, Global, Deals by Geography (%), 2007-2012 108

List of Figures


Figure 1: Rheumatology Therapeutics Market, Global, Revenue Forecasts ($bn),  2005-2018 14
Figure 2: Rheumatology Therapeutics Market, Global, Annual Cost of Therapy ($),  2005-2018 16
Figure 3: Rheumatology Therapeutics Market, Global, Treatment Usage Patterns (million), 2005-2018 18
Figure 4: Rheumatology Therapeutics Market, The US, Revenue Forecasts ($bn),  2005-2018 21
Figure 5: Rheumatology Therapeutics Market, The US, Annual Cost of Therapy ($), 2005-2018 22
Figure 6: Rheumatology Therapeutics Market, The US, Treatment Usage Patterns (million), 2005-2018 24
Figure 7: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2005-2018 26
Figure 8: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2005-2018 27
Figure 9: Rheumatology Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2005-2018 29
Figure 10: Rheumatology Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2005-2018 30
Figure 11: Rheumatology Therapeutics Market, Japan, Revenue Forecasts ($bn),  2005-2018 32
Figure 12: Rheumatology Therapeutics Market, Japan, Annual Cost of Therapy ($), 2005-2018 34
Figure 13: Rheumatology Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2005-2018 36
Figure 14: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2005-2018 47
Figure 15: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2005-2018 48
Figure 16: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2018 50
Figure 17: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Pattern (million), 2005-2018 51
Figure 18: Rheumatoid Arthritis Therapeutics Market, Rheumatoid Arthritis, Treatment Flow Algorithm 53
Figure 19: Rheumatoid Arthritis Therapeutics Market, Drivers and Barriers 53
Figure 20: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn),  2005-2018 57
Figure 21: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($m),  2005-2018 59
Figure 22: Osteoarthritis Therapeutics Market, Global, Annual Cost of Therapy ($),  2005-2018 61
Figure 23: Osteoarthritis Therapeutics Market, Global, Osteoarthritis Pain Treatment Algorithm 62
Figure 24: Osteoarthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2005-2018 63
Figure 25: Osteoarthritis Therapeutics Market, Global, Drivers and Barriers 65
Figure 26: Gout Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2018 68
Figure 27: Gout Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2005-2018 70
Figure 28: Gout Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2018 72
Figure 29: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions),  2005-2018 73
Figure 30:  Gout Therapeutics Market, Treatment Flow Algorithm for Gout 75
Figure 31: Gout Therapeutics Market, Global, Drivers and Barriers 75
Figure 32: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2018 79
Figure 33: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2005-2018 81
Figure 34: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2018 83
Figure 35: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2005-2018 85
Figure 36: Systemic Lupus Erythematosus Therapeutics Market, Treatment Flow Algorithm 87
Figure 37: Systemic Lupus Erythematosus Therapeutics Market, Global, Drivers and Barriers 87
Figure 38: Rheumatology Therapeutics Market, Global, Pipeline Molecules by Stage of Development, May, 2012 89
Figure 39: Rheumatology Therapeutics Market, Abbott, SWOT Analysis 96
Figure 40: Rheumatology Therapeutics Market, Amgen, SWOT Analysis 98
Figure 41: Rheumatology Therapeutics Market, Pfizer, SWOT Analysis 100
Figure 42: Rheumatology Therapeutics Market, Janssen Biotech, SWOT Analysis 102
Figure 43: Rheumatology Therapeutics Market, Merck, SWOT Analysis 104
Figure 44: Rheumatology Therapeutics Market, Global, Deals by Type of Agreement (%), 2007-2012 106
Figure 45: Rheumatology Therapeutics Market, Global, Deals by Year, 2007-2012 107
Figure 46: Rheumatology Therapeutics Market, Global, Deals by Geography (%),  2007-2012 108
Figure 47: GBI Research Market Forecasting Model 119

Upcoming Reports:

Carbide Minerals Market - Global Industry Analysis, Size, Share, Trends And Forecast 2014 - 2020
By - Transparency Market Research
Carbide minerals typically comprise types of minerals such as cohenite, haxonite, moissanite and tongbaite. Out of all these types, moissanite is the most important and widely used carbide mineral across the globe. Silicon carbide, which occurs in nature as rarest of rare mineral moissanite, is used in a diverse range of applications such as abrasives and cutting tools, automobile parts, structural materials, electric systems, power electronic devices, LEDs, astronomy, heating elements, thin filament pyrometry, jewelry, nuclear fuel cladding, nuclear fuel particles, catalyst support, steel...
Next Generation Sequencers Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Next generation sequencers are used inthe sequencing technologies which massively parallelize the DNA sequencing process rather than being limited to single or few fragments of DNA. The next generation sequencing (NGS) technology enables rapid sequencing and produce thousands and millions of sequences in single run with the use of next generation sequencers. Such technologies have been rapidly developing owing to continuous demand for high-throughput (next generation) sequencers which tend to lower the cost of DNA sequencing.  The global next generation sequencers market is...
Home Security Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018
By - Transparency Market Research
Home security is a growing global market due to the need for safety and increasing crime rates in different parts of the world. The electronic security equipments market foresees tremendous growth potential in the upcoming years due to the growing demand for home security solutions. Security solutions in the residential sector is experiencing significant growth since the past few years due to the adoption of electronic security solutions and the increasing rates of burglary, and attractive insurance policies to residents for installing the security systems.  Despite the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...
Second Treaty Between Zealand And Boehringer Ingelheim
Jul 30, 2014  
Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma.  Both these companies are aiming...
Export market in New Zealand driven by innovative and high-value food products
Jul 29, 2014  
Demand for beverages and high value foods in Asia are driving the food and beverage industry in New Zealand. Also there is high demand for dairy products, seafood, meat and processed foods in the Asian economies which fuel the give an export boost to the economy of New Zealand.  Asia has a rapidly growing market for food which in turn is highly beneficial for New Zealand’s export...
Sony plans revival of PlayStation with network services
Jul 29, 2014  
After a nearly USD 10 billion loss over the last six years, Sony Corp has plans of reviving its consumer electronics hero – the PlayStation. Sony will be repositioning the video game console as a center of streamed network services such as social media, music and movies apart from games. The matter is still in its infancy stage of discussion and the plan is to generate revenue from the...